Idiopathic pulmonary fibrosis (IPF), the most common phenotype of IIPs, has a prognosis that is influenced by a number of ...

The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

Good afternoon, and welcome to the MannKind Corporation third quarter 2024 financial results earnings call. As a reminder, ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsMichael Castagna - CEOChris Prentiss ...

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics ...

Living with IPF is never dull, says columnist Sam Kirton, who shares some updates on topics he's discussed in recent columns.

A recent study showed that the COPD assessment test was reliable and responsive for assessing health status in fibrotic ...

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced a ...

Panagiotis Tarinidis has unofficially exceeded the U66KG IPF Raw Total World Record with a score of 713 kilograms (1,571.9 ...

As people live longer than ever before, the incidence of aging-related, chronic diseases is on the rise, severely impacting ...